Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANEB Anebulo Pharmaceuticals	$1.52 -1.3%	$1.13	$0.80 ▼ $3.08	$63.27M	-1.15	18,468 shs	8,234 shs
BIOR Biora Therapeutics	$0.15 +6.5%	$0.14	$0.15 ▼ $7.90	$660K	1.12	76,569 shs	16,292 shs
BOLT Bolt Biotherapeutics	$5.60 -3.3%	$6.61	$5.20 ▼ $15.60	$11.10M	0.92	10,872 shs	11,965 shs
GANX Gain Therapeutics	$1.69 -4.5%	$1.87	$0.89 ▼ $3.19	$53M	0.11	297,531 shs	312,827 shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANEB Anebulo Pharmaceuticals	0.00%	+10.79%	+37.50%	-2.53%	-42.54%
BIOR Biora Therapeutics	0.00%	0.00%	+7.68%	+11.89%	-97.85%
BOLT Bolt Biotherapeutics	0.00%	-5.08%	-10.09%	-33.84%	-61.39%
GANX Gain Therapeutics	0.00%	+2.31%	-1.67%	-23.71%	+37.21%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ANEB Anebulo Pharmaceuticals	2.7737 of 5 stars	3.5	5.0	0.0	1.7	0.0
BIOR Biora Therapeutics	1.7841 of 5 stars	3.5	0.0	0.0	2.5	0.6
BOLT Bolt Biotherapeutics	3.092 of 5 stars	3.2	5.0	0.0	3.3	1.3
GANX Gain Therapeutics	1.7052 of 5 stars	3.6	3.0	0.6	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANEB Anebulo Pharmaceuticals	3.00	Buy	$5.50	261.84% Upside
BIOR Biora Therapeutics	3.00	Buy	$23.00	15,664.22% Upside
BOLT Bolt Biotherapeutics	2.33	Hold	$50.00	792.86% Upside
GANX Gain Therapeutics	3.17	Buy	$8.20	385.21% Upside

Current Analyst Ratings Breakdown

Latest GANX, BOLT, BIOR, and ANEB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/20/2025	BOLT Bolt Biotherapeutics	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$80.00
5/19/2025	GANX Gain Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00 ➝ $8.00
5/15/2025	ANEB Anebulo Pharmaceuticals	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$6.00 ➝ $3.00
5/13/2025	BOLT Bolt Biotherapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold ➝ Hold	$25.00 ➝ $20.00
3/28/2025	GANX Gain Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00 ➝ $6.00
3/25/2025	BOLT Bolt Biotherapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
3/25/2025	BOLT Bolt Biotherapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold ➝ Hold	$30.00 ➝ $25.00

(Data available from 6/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANEB Anebulo Pharmaceuticals	N/A	N/A	N/A	N/A	$0.15 per share	N/A
BIOR Biora Therapeutics	$892K	0.74	N/A	N/A	($36.43) per share	0.00
BOLT Bolt Biotherapeutics	$7.69M	1.40	N/A	N/A	$29.89 per share	0.19
GANX Gain Therapeutics	$50K	1,012.31	N/A	N/A	$0.28 per share	6.04

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANEB Anebulo Pharmaceuticals	-$8.20M	-$0.26	N/A	∞	N/A	N/A	-90.11%	-84.53%	N/A
BIOR Biora Therapeutics	-$124.11M	-$13.04	N/A	N/A	N/A	N/A	N/A	-332.47%	8/11/2025 (Estimated)
BOLT Bolt Biotherapeutics	-$63.12M	-$33.40	N/A	N/A	N/A	-665.56%	-94.51%	-59.07%	8/12/2025 (Estimated)
GANX Gain Therapeutics	-$20.41M	-$0.86	N/A	N/A	N/A	N/A	-247.55%	-146.06%	8/6/2025 (Estimated)

Latest GANX, BOLT, BIOR, and ANEB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	GANX Gain Therapeutics	-$0.16	-$0.16	N/A	-$0.16	$0.03 million	N/A
5/13/2025	Q3 2025	ANEB Anebulo Pharmaceuticals	-$0.05	-$0.04	+$0.01	-$0.04	N/A	N/A
5/12/2025	Q1 2025	BOLT Bolt Biotherapeutics	-$6.80	-$5.80	+$1.00	-$0.29	$0.77 million	$1.22 million
3/27/2025	Q4 2024	GANX Gain Therapeutics	-$0.18	-$0.11	+$0.07	-$0.11	N/A	N/A
3/24/2025	Q4 2024	BOLT Bolt Biotherapeutics	-$7.60	-$7.60	N/A	-$0.42	$0.79 million	$0.01 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANEB Anebulo Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BIOR Biora Therapeutics	N/A	N/A	N/A	N/A	N/A
BOLT Bolt Biotherapeutics	N/A	N/A	N/A	N/A	N/A
GANX Gain Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANEB Anebulo Pharmaceuticals	N/A	25.29	25.29
BIOR Biora Therapeutics	N/A	0.05	0.05
BOLT Bolt Biotherapeutics	0.48	3.13	3.13
GANX Gain Therapeutics	0.05	2.22	2.22

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANEB Anebulo Pharmaceuticals	28.40%
BIOR Biora Therapeutics	43.74%
BOLT Bolt Biotherapeutics	86.70%
GANX Gain Therapeutics	11.97%

Insider Ownership

Company	Insider Ownership
ANEB Anebulo Pharmaceuticals	80.60%
BIOR Biora Therapeutics	51.08%
BOLT Bolt Biotherapeutics	30.90%
GANX Gain Therapeutics	7.18%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANEB Anebulo Pharmaceuticals	4	41.08 million	7.97 million	Not Optionable
BIOR Biora Therapeutics	120	4.52 million	2.21 million	Optionable
BOLT Bolt Biotherapeutics	90	1.92 million	1.33 million	Not Optionable
GANX Gain Therapeutics	20	29.95 million	27.80 million	Optionable

GANX, BOLT, BIOR, and ANEB Headlines

Recent News About These Companies

Gain Therapeutics, Inc. (NASDAQ:GANX) Receives $8.20 Consensus PT from Analysts

June 18, 2025 | americanbankingnews.com

Gain Therapeutics, Inc. (NASDAQ:GANX) Given Consensus Rating of "Buy" by Analysts

June 15, 2025 | marketbeat.com

Gain Therapeutics to Participate in Upcoming Investor Conferences

June 10, 2025 | globenewswire.com

Gain Therapeutics, Inc. Announces Oral Presentation at GBA1 Meeting 2025 in Montreal

May 29, 2025 | quiverquant.com

Gain Therapeutics Announces Oral Presentation at 2nd GBA1 Meeting

May 29, 2025 | globenewswire.com

HC Wainwright Issues Optimistic Forecast for GANX Earnings

May 23, 2025 | marketbeat.com

Gotham Asset Management LLC Sells 176,437 Shares of Gain Therapeutics, Inc. (NASDAQ:GANX)

May 23, 2025 | marketbeat.com

Gain Therapeutics, Inc. (NASDAQ:GANX) Given Average Rating of "Buy" by Analysts

May 23, 2025 | marketbeat.com

Gain Therapeutics (GANX) Gets a Buy from Scotiabank

May 16, 2025 | theglobeandmail.com

Gain Therapeutics, Inc.: Gain Therapeutics Reports Financial Results for First Quarter 2025 and Provides Corporate Update

May 14, 2025 | finanznachrichten.de

Gain Therapeutics Reports Financial Results for First Quarter 2025 and Provides Corporate Update

May 14, 2025 | globenewswire.com

Gain Therapeutics Presents Preclinical Data at IAPRD 2025 30th World Congress on Parkinson’s Disease and Related Disorders

May 13, 2025 | finance.yahoo.com

Gain Therapeutics Presents Preclinical Data at IAPRD 2025 30th World Congress on Parkinson's Disease and Related Disorders

May 12, 2025 | globenewswire.com

Gain Therapeutics to Participate at The Citizens Life Sciences Conference

May 1, 2025 | globenewswire.com

Gain Therapeutics Announces Oral Poster Presentation at IAPRD 2025 30th World Congress on Parkinson’s Disease and Related Disorders

April 30, 2025 | finance.yahoo.com

Gain Therapeutics Announces Oral Poster Presentation at IAPRD 2025 30th World Congress on Parkinson's Disease and Related Disorders

April 30, 2025 | globenewswire.com

Gain Therapeutics presents additional data on study of GT-02287

April 11, 2025 | markets.businessinsider.com

Is Gain Therapeutics (GANX) the Top Healthcare Stock to Buy According to Billionaire David Einhorn?

April 11, 2025 | insidermonkey.com

Gain Therapeutics Presents Additional Preclinical Data and Design of Phase 1b Clinical Study of GT-02287 at AD/PD 2025 and Provides Enrollment Update

April 10, 2025 | manilatimes.net

Gain Therapeutics (GANX) Receives a Buy from Roth MKM

March 31, 2025 | markets.businessinsider.com

Gain Therapeutics, Inc.: Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2024 and Provides Corporate Update

March 28, 2025 | finanznachrichten.de

New MarketBeat Followers Over Time

Media Sentiment Over Time

GANX, BOLT, BIOR, and ANEB Company Descriptions

Anebulo Pharmaceuticals NASDAQ:ANEB

$1.52 -0.02 (-1.30%)

Closing price 04:00 PM Eastern

Extended Trading

$1.44 -0.08 (-4.93%)

As of 07:35 PM Eastern

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas.

Biora Therapeutics NASDAQ:BIOR

$0.15 +0.01 (+6.50%)

As of 06/13/2025

Biora Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing oral biotherapeutics in the United States. The company offers NaviCap, a targeted oral delivery platform for delivery of therapeutics in the gastrointestinal tract to enhance the treatment of inflammatory bowel diseases; and BioJet, a systemic oral delivery platform designs to replace injection with needle-free, oral delivery of large molecules for management of chronic diseases. The company was formerly known as Progenity, Inc. and changed its name to Biora Therapeutics, Inc. in April 2022 to reflect its focus on its therapeutics pipeline. Biora Therapeutics, Inc. was founded in 2010 and is headquartered in San Diego, California.

Bolt Biotherapeutics NASDAQ:BOLT

$5.60 -0.19 (-3.28%)

Closing price 04:00 PM Eastern

Extended Trading

$5.62 +0.02 (+0.36%)

As of 06:29 PM Eastern

Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.

Gain Therapeutics NASDAQ:GANX

$1.69 -0.08 (-4.52%)

Closing price 04:00 PM Eastern

Extended Trading

$1.72 +0.03 (+2.01%)

As of 07:57 PM Eastern

Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials. It also has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer's Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time